The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
A systematic review of humoral immune responses against tumor antigens
Open accessAbstract
This review summarizes studies on humoral immune responses against tumor-associated antigens (TAAs) with a focus on antibody frequencies and the potential diagnostic, prognostic, and etiologic relevance of antibodies against TAAs. We performed a systematic literature search in Medline and identified 3,619 articles on humoral immune responses and TAAs. In 145 studies, meeting the inclusion criteria, humoral immune responses in cancer patients have been analyzed against over 100 different TAAs. The most frequently analyzed antigens were p53, MUC1, NY-ESO-1, c-myc, survivin, p62, cyclin B1, and Her2/neu. Antibodies against these TAAs were detected in 0–69% (median 14%) of analyzed tumor patients. Antibody frequencies were generally very low in healthy individuals, with the exception of few TAAs, especially MUC1. For several TAAs, including p53, Her2/neu, and NY-ESO-1, higher antibody frequencies were reported when tumors expressed the respective TAA. Antibodies against MUC1 were associated with a favorable prognosis while antibodies against p53 were associated with poor disease outcome. These data suggest different functional roles of endogenous antibodies against TAAs. Although data on prediagnostic antibody levels are scarce and antibody frequencies for most TAAs are at levels precluding use in diagnostic assays for cancer early detection, there is some promising data on achieving higher sensitivity for cancer detection using panels of TAAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
Human tumor antigens recognized by T lymphocytes.
Boon, T., & van der Bruggen, P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.725 · Cited by 842
Finn, O. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072739 · Cited by 774
A fresh look at tumor immunosurveillance and immunotherapy
Smyth, M. J., Godfrey, D. I., & Trapani, J. A. (2001) · Nature Immunology · doi:10.1038/86297 · Cited by 745
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
Stockert, E., Jäger, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., & Old, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1349 · Cited by 698
A listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi, T. (2000) · PubMed · Cited by 550
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.
Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, A. E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., & Livingston, R. B. (1994) · PubMed · Cited by 524
Kamradt, T., & Mitchison, N. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440907 · Cited by 457
Cancer antigens: immune recognition of self and altered self.
Houghton, A. N. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.1 · Cited by 420
B cells inhibit induction of T cell-dependent tumor immunity
Qin, Z., Richter, G., Schüler, T., Ibe, S., Cao, X., & Blankenstein, T. (1998) · Nature Medicine · doi:10.1038/nm0598-627 · Cited by 419
Humoral immunity, inflammation and cancer
Tan, T.-T., & Coussens, L. M. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.001 · Cited by 417
Wesseling, J., van der Valk, S. W., & Hilkens, J. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.4.565 · Cited by 380
Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., & Cheever, M. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3363 · Cited by 345
Serum p53 antibodies as early markers of lung cancer
Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals, D., Hirsch, A., & Soussi, T. (1995) · Nature Medicine · doi:10.1038/nm0795-701 · Cited by 318
Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
Agrawal, B., Krantz, M. J., Reddish, M. A., & Longenecker, B. M. (1998) · Nature Medicine · doi:10.1038/nm0198-043 · Cited by 294
Autoantibodies in lung cancer: possibilities for early detection and subsequent cure
Chapman, C. J., Murray, A., McElveen, J. E., Sahin, U., Luxemburger, U., Tureci, O., Wiewrodt, R., Barnes, A. C., & Robertson, J. F. (2008) · Thorax · doi:10.1136/thx.2007.083592 · Cited by 288
Schlichtholz, B., Legros, Y., Gillet, D., Fruchart‐Gaillard, C., Marty, M. E., Lane, D. P., Calvo, F. M., & Soussi, T. (1992) · PubMed · Cited by 274
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
Davidoff, A. M., Iglehart, J. D., & Marks, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3439 · Cited by 272
Oncogenic protein tyrosine kinases: Kit as a human oncogenic tyrosine kinase
Kitamura, Y., & Hirotab, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4273-y · Cited by 260
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.
Zhang, J.-Y., Casiano, C. A., Peng, X.-X., et al. (2003) · PubMed · Cited by 244
von Mensdorff-Pouilly, S., Verstraeten, A. A., Kenemans, P., Snijdewint, F. G. M., Kok, A., Van Kamp, G. J., Paul, M. A., Van Diest, P. J., Meijer, S., & Hilgers, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.574 · Cited by 233
Jäger, E., Stockert, E., Zidianakis, Z., Chen, Y.-T., Karbach, J., Jäger, D., Arand, M., Ritter, G., Old, L. J., & Knuth, A. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<506::aid-ijc10>3.0.co;2-6 · Cited by 227
p53 in colorectal cancer: clinicopathological correlation and prognostic significance
Scott, N., Sagar, P., Stewart, J., Blair, G., Dixon, M., & Quirke, P. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.74 · Cited by 212
Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Trédaniel, J., Hirsch, A., de Fromentel, C. C., Preudhomme, C., Fenaux, P., Fournier, G., et al. (1993) · PubMed · Cited by 173
Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Hamanaka, Y., Suehiro, Y., Fukui, M., Shikichi, K., Imai, K., & Hinoda, Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10801 · Cited by 165
Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.
Koziol, J. A., Zhang, J.-Y., Casiano, C. A., Peng, X.-X., Shi, F., Feng, A. C., Chan, E. K. L., & Tan, E. M. (2003) · PubMed · Cited by 164
Anderson, K. S., Ramachandran, N., Wong, J., Raphael, J. V., Hainsworth, E., Demirkan, G., Cramer, D. W., Aronzon, D., Hodi, F. S., Harris, L. N., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr700804c · Cited by 148
Cramer, D. W., Titus-Ernstoff, L. T., McKolanis, J., Welch, W. R., Vitonis, A. F., Berkowitz, R. S., & Finn, O. J. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0035 · Cited by 139
Schlichtholz, B., Trédaniel, J., Lubin, R., Zalcman, G., Hirsch, A., & Soussi, T. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.159 · Cited by 139
Korangy, F., Ormandy, L. A., Bleck, J. S., Klempnauer, J. L., Wilkens, L., Manns, M. P., & Greten, T. F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0181 · Cited by 138
Oncogenic protein tyrosine kinases
M�nard, S., Casalini, P., Campiglio, M., Pupa, S. M., & Tagliabue, E. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4277-7 · Cited by 137
Analysis of the anti-p53 antibody response in cancer patients.
Labrecque, S., Naor, N., Thomson, D. M., & Matlashewski, G. (1993) · PubMed · Cited by 136
Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies.
Imai, H., Ochs, R., Kiyosawa, K., et al. (1992) · PubMed · Cited by 130
Lubin, R., Schlichtholz, B., Teillaud, J., Garay, E., BUSSEL, A., & Wild, C. P. (1995) · PubMed · Cited by 129
Natural Autoantibody to MUC1 Is a Prognostic Indicator for Non–Small Cell Lung Cancer
Hirasawa, Y., Kohno, N., Yokoyama, A., KONDO, K., Hiwada, K., & Miyake, M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9905028 · Cited by 127
HER2/neu role in breast cancer: from a prognostic foe to a predictive friend
Ferretti, G., Felici, A., Papaldo, P., Fabi, A., & Cognetti, F. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328012980a · Cited by 123
Yonezawa, S., Goto, M., Yamada, N., Higashi, M., & Nomoto, M. (2008) · PROTEOMICS · doi:10.1002/pmic.200800040 · Cited by 115
Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients
Gourevitch, M. M., von Mensdorff‐Pouilly, S., Litvinov, S. V., Kenemans, P., van Kamp, G. J., Verstraeten, A. A., & Hilgers, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.436 · Cited by 108
Analysis of p53 Serum Antibodies in Patients With Head and Neck Squamous Cell Carcinoma
Bourhis, J., Lubin, R., Roche, B., Koscielny, S., Bosq, J., Dubois, I., Talbot, M., Marandas, P., Schwaab, G., Wibault, P., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.17.1228 · Cited by 100
Antigen‐specific immunotherapy and cancer vaccines
Jäger, E., Jäger, D., & Knuth, A. K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11292 · Cited by 95
Zhang, J.-Y., Megliorino, R., Peng, X.-X., Tan, E. M., Chen, Y., & Chan, E. K. L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.08.010 · Cited by 91
Challenges and prospects of immunotherapy as cancer treatment
Rescigno, M., Avogadri, F., & Curigliano, G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.003 · Cited by 84
Multiple pathways to tumor immunity and concomitant autoimmunity
Turk, M. J., Wolchok, J. D., Guevara-Patino, J. A., Goldberg, S. M., & Houghton, A. N. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18811.x · Cited by 83
What Makes MUC1 a Tumor Antigen?
Karsten, U. R., von Mensdorff‐Pouilly, S., & Goletz, S. (2005) · Tumor Biology · doi:10.1159/000086956 · Cited by 83
Montgomery, B., Makary, E., Schiffman, K., Vivian Goodell, A., & Disis, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.650.65.2 · Cited by 82
NY‐ESO‐1 protein expression and humoral immune responses in prostate cancer
Fosså, A., Berner, A., Fosså, S. D., Hernes, E., Gaudernack, G., & Smeland, E. B. (2004) · The Prostate · doi:10.1002/pros.20025 · Cited by 79
Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1
Türeci, Ö., Mack, U., Luxemburger, U., Heinen, H., Krummenauer, F., Sester, M., Sester, U., Sybrecht, G. W., & Şahin, U. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.008 · Cited by 77
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.
Kim, J., Herlyn, D., Wong, K., Park, D. C., Schorge, J. O., Lu, K. H., Skates, S. J., Cramer, D. W., Berkowitz, R. S., & Mok, S. C. (2003) · PubMed · Cited by 77
Zhang, J., Zhu, W., Imai, H., Kiyosawa, K., Chan, E. K. L., & Tan, E. M. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01585.x · Cited by 75
Reuschenbach, M., Waterboer, T., Wallin, K., Einenkel, J., Dillner, J., Hamšíková, E., Eschenbach, D., Zimmer, H., Heilig, B., Kopitz, J., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23837 · Cited by 70
Self-citationHumoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies
Looi, K., Megliorino, R., Shi, F., Peng, X.-X., Chen, Y., & Zhang, J.-Y. (2006) · Oncology Reports · doi:10.3892/or.16.5.1105 · Cited by 70
Volkmann, M., Müller, M., Hofmann, W. J., Meyer, M., Hagelstein, J., Räth, U., Kommerell, B., Zentgraf, H., & Galle, P. R. (1993) · Hepatology · doi:10.1002/hep.1840180313 · Cited by 70
Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan, R., Nath, N., Agarwal, S., Mathur, M., Wasylyk, B., & Shukla, N. K. (1998) · PubMed · Cited by 66
Autoimmune Responses to mRNA Binding Proteins p62 and Koc in Diverse Malignancies
Zhang, J.-Y., Chan, E. K. L., Peng, X.-X., Lu, M., Wang, X., Mueller, F., & Tan, E. M. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5048 · Cited by 65
Fishman, P., Merimski, O., Baharav, E., & Shoenfeld, Y. (1997) · Cancer · Cited by 65
Maio, M., Coral, S., Sigalotti, L., Elisei, R., Romei, C., Rossi, G., Cortini, E., Colizzi, F., Fenzi, G., Altomonte, M., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020830 · Cited by 65
Humoral immune response against p53 protein in patients with colorectal carcinoma
Angelopoulou, K., Stratis, M., & Diamandis, E. P. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970106)70:1<46::aid-ijc7>3.0.co;2-6 · Cited by 62
Ralhan, R., Arora, S., Chattopadhyay, T. K., Shukla, N. K., & Mathur, M. (2000) · International Journal of Cancer · Cited by 61
Shi, F., Zhang, J., Liu, D., Rearden, A., Elliot, M. L., Nachtsheim, D., Daniels‐Wells, T. R., Casiano, C. A., Heeb, M. J., Chan, E. K. L., et al. (2004) · The Prostate · doi:10.1002/pros.20181 · Cited by 58
Capitalizing on the Immunogenicity of Dying Tumor Cells
Fonseca, C., & Dranoff, G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2245 · Cited by 56
Profiling Tumor-Associated Autoantibodies for the Detection of Colon Cancer
Ran, Y., Hu, H., Zhou, Z., Yu, L., Sun, L., Pan, J. G., Liu, J., & Yang, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2021 · Cited by 53
Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection
Chen, Y., Lin, P. P., Qiu, S., Peng, X.-X., Looi, K., Farquhar, M. G., & Zhang, J.-Y. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.5.1137 · Cited by 51
Hammel, P. R., Leroy, K., Chaumette, M. T., Villaudy, J., Falzone, M.-C., Rouillard, D., Hamelin, R., Boissier, B., & Remvikos, Y. (1999) · International Journal of Cancer · Cited by 48
NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer
Akçakanat, A., Kanda, T., Koyama, Y., Watanabe, M., Kimura, E., Yoshida, Y., Komukai, S., Nakagawa, S., Odani, S., Fujii, H., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0768-3 · Cited by 46
Bachelot, T., Ratel, D., Ménétrier‐Caux, C., Wion, D., Blay, J., & Berger, F. R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603037 · Cited by 39
Cancer vaccines targeting the HER2/ oncogenic protein
Disis, M. L. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90104-6 · Cited by 38
Serological immune response to cancer testis antigens in patients with pancreatic cancer
Wadle, A., Kubuschok, B., Imig, J., Wüllner, B., Wittig, C., Zwick, C., Mischo, A., Wätzig, K., Romeike, B. F. M., Lindemann, W., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21744 · Cited by 37
Kurtenkov, O. A., Klaamas, K., Rittenhouse‐Olson, K., Vahter, L., Sergejev, B., Miljukhina, L., & Shljapnikova, L. (2005) · PubMed · Cited by 31
Ersvær, E., Zhang, J., McCormack, E., Olsnes, A. M., Ånensen, N., Tan, E. M., Gjertsen, B. T., & Bruserud, Ø. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00899.x · Cited by 31
HER2/neu Expression in Relation to Clinicopathologic Features of Breast Cancer Patients
Traina, A., Agostara, B., Marasà, L., Calabrò, M., Zarcone, M., & Carruba, G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1386.029 · Cited by 26
p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
Creaney, J., McLaren, B., Stevenson, S., Musk, A. W., de Klerk, N. H., Robinson, B. W. S., & Lake, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1529 · Cited by 22
Malignancy‐induced autoimmunity to MUC1: initial antibody characterization
Graves, C. R. L., Robertson, J. F. R., Murray, A., Price, M. R., & Chapman, C. J. (2005) · Journal of Peptide Research · doi:10.1111/j.1399-3011.2005.00297.x · Cited by 15
Selter, H., Schmidt, G., Villena-Heinsen, C. E., & Montenarh, M. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00356-5 · Cited by 2
Cited by
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 524
Metadata
- Authors
- Reuschenbach, M., von Knebel Doeberitz, M., & Wentzensen, N.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2009-06-28
- Volume
- 58
- Issue
- 10
- Pages
- 1535-1544
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W1987908689
- Cited by
- 280
- References
- 75
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.